Dicerna Pharmaceuticals Inc
F:DPL
Operating Margin
Dicerna Pharmaceuticals Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
D
|
Dicerna Pharmaceuticals Inc
F:DPL
|
2.6B EUR |
-63%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-17 527%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
344.8B USD |
30%
|
|
| US |
|
Cyclo Therapeutics Inc
NASDAQ:CYTH
|
325.9B USD |
-2 834%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
159.6B USD |
25%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
140.9B USD |
38%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
118.9B USD |
38%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-370%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
127.9B AUD |
26%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
60.5B USD |
29%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
51.9B USD |
-5%
|
Dicerna Pharmaceuticals Inc
Glance View
In the unassuming landscape of biotechnology, Dicerna Pharmaceuticals Inc. carved its niche with the finesse of a sculptor hewing masterpieces from marble. Founded in 2007, this Lexington-based company embarked on its journey into the realm of RNA interference (RNAi) therapies, a revolutionary approach that tackles diseases by silencing specific genes. RNAi is akin to flipping a switch within our genetic blueprint, modulating the expression of proteins that could potentially cause disorders. Dicerna's proprietary GalXC™ technology emerged as the linchpin of its innovation, allowing the company to create targeted therapies that had the potential to address a diverse array of rare and chronic diseases such as primary hyperoxaluria, chronic liver diseases, and viral infections. Dicerna's business model weaved together research prowess and strategic alliances, capitalizing on partnerships with big pharmaceutical titans like Novo Nordisk, Roche, Boehringer Ingelheim, and Eli Lilly to propel its research pipeline. These collaborations not only provided the necessary capital but also amplified its scientific discoveries to reach broader horizons. Licensing agreements allowed Dicerna to earn milestone payments along with royalties on eventual sales, enabling it to reinvest in groundbreaking research and development. While playing the long game in the volatile waters of biotechnology, Dicerna's revenue strategy relied heavily on these partnerships, as well as on advancing its in-house programs to bring its therapies closer to market, painting a picture of a company poised at the confluence of scientific promise and commercial potential.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Dicerna Pharmaceuticals Inc's most recent financial statements, the company has Operating Margin of -62.9%.
You don't have any saved screeners yet